UBS Group
CLDI icon

UBS Group’s Calidi Biotherapeutics CLDI Stock Holding History

UBS Group’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34K Buy
+493
New +$1.59K ﹤0.01% 9578
2026
Q1 		– Sell
-470
Closed -$8.79K – 10570
2025
Q4 		$8.79K Buy
470
+310
+194% +$7.3K ﹤0.01% 8334
2025
Q3 		$3.9K Sell
160
-74
-32% -$5.03K ﹤0.01% 8996
2025
Q2 		$10.3K Buy
+234
New +$18.2K ﹤0.01% 8845
2025
Q1 		– Sell
-46
Closed -$8.39K – 10161
2024
Q4 		$10.1K Buy
46
+41
+820% +$12.3K ﹤0.01% 8318
2024
Q3 		$1.05K Buy
+5
New +$1.39K ﹤0.01% 8733
2024
Q2 		– Hold
0
– – – 9418
2024
Q1 		– Hold
0
– – – 9132
2023
Q4 		– Hold
0
– – – 9090
2023
Q3 		– Hold
0
– – – 9064
2023
Q2 		– Hold
0
– – – 8497
2023
Q1 		– Hold
0
– – – 9220
2022
Q4 		– Hold
0
– – – 10284
2022
Q3 		– Sell
-1
Closed -$16K – 10396
2022
Q2 		$16K Hold
1
– – ﹤0.01% 7181
2022
Q1 		$15K Sell
1
-3
-75% -$56.7K ﹤0.01% 7819
2021
Q4 		$73K Buy
+4
New +$75.4K ﹤0.01% 6570

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group's CLDI Position: Q2 2026 in Review

UBS Group opened a new position in Calidi Biotherapeutics (CLDI) in Q2 2026: 493 shares worth $1.34K. The stake represents ﹤0.01% of the portfolio and ranks #9578 among its holdings. This is a return to the name: UBS Group previously reported a position in CLDI as recently as Q4 2025.

UBS Group first reported a position in CLDI in Q4 2021 and has held it in 9 quarters since. The position peaked at $73K in Q4 2021. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • UBS Group held 493 shares of Calidi Biotherapeutics worth $1.34K as of Q2 2026.
  • Calidi Biotherapeutics was a new UBS Group position in Q2 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9578 holding.
  • UBS Group first reported a position in Calidi Biotherapeutics in Q4 2021 and has held it in 9 quarters since.
  • UBS Group's Calidi Biotherapeutics position peaked at $73K in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.